drugset / Trial / NCT06088459
NWRD06 DNA Plasmid for HCC After Radical Resection
NaSequentialOpen-labelTreatment
Summary
This is a dose escalation Phase 1 clinical study to evaluate the safety and immunogenicity of Glypican3 (GPC3)-targeted DNA plasmid vaccine (NWRD06) in patients with GPC3-positive primary hepatocellular carcinoma after radical resection.
Timeline
- Start
- 2023-11
- Primary completion
- 2024-12
- Completion
- 2025-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NWRD06 | Vaccine | 1 mg | Intramuscular |
| Subject | NWRD06 | Vaccine | 4 mg | Intramuscular |
| Subject | NWRD06 | Vaccine | 8 mg | Intramuscular |